Abstract
Significant changes in the Spanish pharmaceutical market were introduced during the period 1998–2001. Cost containment has been a major priority for all publicly financed medicines. Its measures included a voluntary contribution from Farmaindustria, a negative list, wholesale and pharmacists margin reductions, generic substitution, a reference price system and price reduction for certain active principles. However, the changes in the Spanish pharmaceutical market have not produced significant savings in public expenditure. The main reason for the continuing rise in this expenditure is the introduction of new, more expensive drugs, which often fail to offer real therapeutic advantages over products already on the market. Measures such as prescribing guidelines, incentives to physicians to meet prescribing budgets, pharmacotherapeutic guides and regular bulletins could be implemented with the aim of prescribing value for money medicines.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rovira J (1998) Mercado de medicamentos en España. Papeles de Economia Española, no 76
Anonymous (1997) Ley 66/1997, de 30 de diciembre, de Medidas Fiscales, Administrativas y del Orden Social, Boletin Oficial del Estado, 31 December
Anonymous (1998)Ley 50/1998, de 30 de diciembre, de Medidas Fiscales, Administrativas y del Orden Social. Boletin Oficial del Estado, 31 December
Anonymous (1999) Real decreto 520/1999, de 26 de marzo, por el que se aprueba el Estatuto de la Agencia Española del Medicamento
Anonymous (1999) Real decreto 669/1999, de 23 de abril, por el que se modifica el Real decreto 1893/1996, de 2 de agosto, de estructura orgánica básica del Ministerio de Sanidad y Consumo, de sus Organismos autónomos y del Instituto Nacional de la Salud
Anonymous (1990) Real Decreto 271/1990, de 23 de febrero, sobre reorganizacion de la intervencion de precios de las especialidades farmaceuticas de uso humano. Boletin Oficial del Estado numero 53. 2 March
Anonymous (1989) Directiva 89/105/CEE, de 21 de diciembre de 1988. Diario Oficial de las Comunidades Europeas L 40, 11 February
Anonymous (1990) Orden de 17 de diciembre de 1990, Boletin Oficial del Estado numero 302, 18 December
Darbà J, Rovira J (1998) Parallel trade of pharmaceuticals in the European Union. Pharmacoeconomics 14 [Suppl 1]:129–136
Puig J (1998) Regulación y competencia de precios en el mercado farmacéutico. Papeles de Economia Española, no 76
Joensson B (1994) Pricing and reimbursement of pharmaceuticals in Sweden. Pharmacoeconomics 6 [Suppl1]:51–60
López-Bastida J, Mossialos E (2000) Pharmaceutical expenditure in Spain: cost and control. Int J Health Services 30:597–619
Rovira J (2002) The role of prices in drug expenditure analysis. HEPAC 3
Anonymous (1997–2002) Ministerio de Sanidad y Consumo. Dirección General de Farmacia y Productos Sanitarios. Resumen de facturación de recetas médicas
Anonymous (2001) Ministerio de Sanidad y Consumo. Informacion Terapeutica del Sistema Nacional de Salud, Madrid
Anonymous (2000) Real decreto-ley 5/2000, de 23 de junio, de Medidas Urgentes de Contención del Gasto Farmacéutico Público de Racionalización del Uso de los Medicamentos. Boletin Oficial del Estad, 24 June
Anonymous (1999) Medicaments generics. Butlleti d'Informacio Terapeutica. Servei Catala de la Salut, vol 11, no 1–
Anonymous (1999) Real decreto 1035/1999, de 18 de junio, por el que se regula el sistema de precios de referencia en la financiación de medicamentos con cargo a fondos de la Seguridad Social o a fondos estatales afectos a la sanidad, Boletin Oficial del Estado, 29 June
Anonymous (1990) Ley 25/1990, de 20 de diciembre, del Medicamento, Boletin Oficial del Estado, no 306, 22 December, Artículos 89:90, 94 de la Ley del Medicamento
Anonymous (1996) Ley 13/1996, de 30 de diciembre, de Medidas Fiscales, Administrativas y de Orden Social, Boletin Oficial del Estado, 31 December 1996
Puig J, López-Casasnovas G (2001) Review of the literature on reference pricing. Health Policy
Mossialos E, Ranos C, Abel-Smith B (eds) (1994) Cost containment, pricing and financing of pharmaceuticals in the European Community: the policy-makers' view. LSE Health and Pharmetrica, Greece
Puig-Junoy J (2002) Analisis economico de la financiacion publica de medicamentos.. Masson, Barcelona
Acknowledgements
The author acknowledges the comments and suggestions received from the participants to the 22nd Meeting of the Spanish Health Economic Association held in Pamplona (Spain), particularly from Joan Rovira, Jaume Puig-Junoy and Antoni Gilabert. The author also thanks two anonymous referees for helpful comments. The errors and omissions of the paper are the responsibility of the author alone.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Darbà, J. Pharmaceutical expenditure in Spain: evolution and cost containment measures during 1998–2001. HEPAC 4, 151–157 (2003). https://doi.org/10.1007/s10198-003-0167-4
Issue Date:
DOI: https://doi.org/10.1007/s10198-003-0167-4